Logo

Pfizer's Retacrit (epoetin alfa-epbx- biosimilar) Receives FDA Approval for Anemia

Share this

Pfizer's Retacrit (epoetin alfa-epbx- biosimilar) Receives FDA Approval for Anemia

Shots:

  • The approval is based on non-inferiority data demonstrating biosimilarity between Retacrit and the reference product- Epogen & Procrit
  • In May- 2016 Pfizer and Vifor Pharma collaborated for the commercialization of retacrit in certain therapeutic areas
  • Retacrit (epoetin alfa) a biosimilar to Epogen & Procrit- is an erythropoiesis-stimulating agent (ESA) indicated for anemia and reduction in allogeneic red blood cell (RBC) transfusion

Ref: Pfizer | Image: Market Exclusive

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions